Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia
Status: Not_yet_recruiting
Location: See all (7) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 35
Healthy Volunteers: f
View:
• Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
• Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Locations
Other Locations
China
Xiangya Hospital of Central South University
Changsha
The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY
Guangxi
Nanfang Hospital, Southern Medical University
Guangzhou
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou
No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
Nanning
Shenzhen Children 's Hospital
Shenzhen
Tianjin Institute of Hematology
Tianjin
Contact Information
Primary
Xiaochen Wang, phD
xcwang@brlmed.com
021-64340008
Time Frame
Start Date: 2024-12-08
Completion Date: 2038-10-15
Participants
Target number of participants: 45
Treatments
BRL-101
All patients who have received BRL-101
Related Therapeutic Areas
Sponsors
Collaborators: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Shenzhen Children's Hospital, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University
Leads: Bioray Laboratories